Precision Medicine in Oncology® | Specialty

Dr. Scagliotti on Treating EGFR-Mutated Tumors with Afatinib

September 23rd 2013

Giorgio V. Scagliotti, MD, PhD, head, Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses treating epidermal growth factor receptor- (EGFR) mutated tumors with afatinib.

Dr. Bunn Discusses Afatinib in Lung Cancer

September 17th 2013

Paul A. Bunn, Jr, MD, professor of medicine in medical oncology, head of the division of medical oncology, University of Colorado, discusses afatinib for patients with activating epidermal growth factor receptor (EGFR) mutation.

Dr. Aghajanian on Ovarian Cancer Trial Endpoints

September 16th 2013

Carol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses the difficulties with a gold standard clinical trial endpoint in ovarian cancer.

Dr. Mok Discusses Developing Lung Cancer Treatments

September 12th 2013

Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.

Penny Daugherty on Discussing Patients' Genetics

September 11th 2013

Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, explains how nurses in her practice discuss genetics and genomics with patients.

Research Team in Canada Explores PARP's Complex Role in DNA Repair

September 9th 2013

Recently, Girish M. Shah's team has been using cellular and murine models to examine various therapeutic options, including inhibitor and gene knockout approaches against the DNA damage-responsive enzyme poly(ADP-ribose) polymerase 1 (PARP-1).

Puma Begins Phase III Development of Neratinib in Breast Cancer

September 6th 2013

Puma Biotechnology is a Los Angeles-based development stage biopharmaceutical company that has spent the last couple of years focused on the development of its lead drug candidate, neratinib (PB272).

Maintenance Olaparib Resurrected for Phase III Program

September 4th 2013

The first patient has been enrolled in a phase III clinical program investigating treatment with olaparib for patients with BRCA-mutated ovarian cancer, marking another step in the revived development of an agent once relegated to the sidelines.

Novel Drug Studies Yield Biomarker Candidates for Prostate Cancer Bone Turnover

September 4th 2013

Prostate cancer has a propensity to metastasize to bone. High turnover ultimately results in a net loss of bone tissue; prostate cancer treatment contributes to the loss of bone integrity, as androgen- deprivation therapy often causes abnormally low bone density

Ginseng Improves Cancer-Related Fatigue in Phase III Trial

September 3rd 2013

A multisite, randomized, double-blind trial evaluating the fatigue-ameliorating properties of American ginseng in cancer patients and recent survivors has found the herb to be helpful in reducing some aspects of CRF, with the benefit strongest among patients currently in treatment.

New Life for PARP Inhibitors: Emerging Agents Leave Mark at ASCO

August 30th 2013

Anticancer agents that inhibit the poly (ADP-ribose) polymerase (PARP) family of enzymes have defined a new therapeutic paradigm known as synthetic lethality.

Did Our Founding Fathers Get It Right?

August 28th 2013

Only Time Will Tell the Far-Reaching Societal Implications of the Supreme Court's BRCA 1/2 Ruling

Dr. Matthew J. Ellis on the Future of TCGA

August 27th 2013

Matthew J. Ellis, MD, PhD, professor, Department of Medicine, Oncology Division, Breast Oncology Section, Washington University School of Medicine in St. Louis, Missouri, discusses the future of The Cancer Genome Atlas project.

Dr. Gaspar on Reducing Neurotoxicity in Lung Cancer

August 26th 2013

Laurie Gaspar, MD, Professor and Chair Department of Radiation Oncology, Grohne Chair in Clinical Oncology, University of Colorado School of Medicine, discusses reducing neurotoxicity in small cell lung cancer patients.

Developments in Metastatic Cancer

August 23rd 2013

Over the past several years, several new approaches to treatment have prolonged and improved quality of life for patients with metastases.

Conclusion: Final Thoughts on Treatment Advances in NSCLC

August 21st 2013

Selecting a First-Line EGFR Inhibitor in NSCLC

August 21st 2013

GALAXY-1 Trial: Investigation of Hsp90 Inhibition in NSCLC

August 21st 2013

Novel Immunotherapy Combinations in NSCLC

August 21st 2013

Targeting the Immune System in Non-Small Cell Lung Cancer

August 21st 2013